Why did you participate in the Biomapas Academy?
Everything started when I had a trip to a career fair during my studies. This was the first time I met Biomapas in person as there were several lecturers that presented the company itself and its activities. I remember thinking that I would like to work with this team as it piqued my interest.
Later, when I was working on my master’s degree, I came across an advertisement on social media for the Biomapas Academy. I already knew that I wanted to learn more about the pharma industry and was interested in various opportunities, so I applied for this opportunity.
How was your experience during the three months?
The Academy was a continuous cycle spanning several months of interesting lectures from true professionals with extensive knowledge. During this short time, I learned a lot about product development, research, safety information and its systems, different possible roles and their responsibilities, and new opportunities where young specialists can grow and find their place in the life sciences industry.
What did the future hold for you after the Academy?
A while after the Academy, I officially became part of Biomapas and its big family! With my background being an MPharm, I was always interested in drug safety. Therefore, I am working in the Pharmacovigilance Department as a Pharmacovigilance Project Management Assistant. I must say there are many interesting things to learn and experience that I am looking forward to with my team.
What would you say to the future participants?
If you are thinking about participating in the Academy, do not hesitate. Being an alumnus, I can say that you will definitely see the pharma industry from within. It will broaden your understanding; you will gain needed knowledge and experience in life sciences and will be able to apply that information working in your chosen field. I hope to see you at Biomapas!
Biomapas Academy
What is Clinical Research? Regulatory Affairs? Pharmacovigilance?
7 Reasons To Include Eastern Europe In Your Clinical Trial Strategy
Choosing the right set of countries, sites and investigators for a clinical trial are critical success factors in any clinical development program. They can guarantee speedy patient recruitment and timely delivery of study results. It also ensures that you conduct...
Company Registration Requirements in MENA: a Prerequisite for Product Registration
Company registration is part of the common regulatory requirements in several Middle Eastern and North African (MENA) countries. Nevertheless, it can be easily overlooked in preparation for drug filing and the overall regulatory picture. MENA countries are accepting...
Biosimilars in the MENA Region: Regulatory Landscape
Regulatory affairs for biosimilars in Middle East North Africa (MENA) region are evolving as existing guidelines and regulatory frameworks are being updated. Since European Medicines Agency (EMA) introduced a legal pathway for biosimilars approval in 2004, several...
Successful Medical Device Registration in EAEU: New Legislation (Part 1)
Webinar: Successful Medical Device Registration in EAEU: New Legislation (Part 1) The webinar discusses and explains the basic, essential, and theoretical matters of the EAEU system, outlines the new approach to the quality, safety, and efficacy assessments, and...
Inga Lakštauskienė – Head of Global Regulatory Affairs Operations
Learn about Inga’s role in managing our regulatory affairs team and coordinating various regulatory projects.
Edita Kaupienė – Senior Pharmacovigilance Project Manager
Explore how Edita’s role supports pharmacovigilance project planning and execution, from strategy to everyday operations.
Megi Muradashvili – Senior Clinical Research Associate
What is your role at Biomapas? My role is Senior Clinical research associate. I am mainly responsible for overseeing clinical trials and their performance in strict accordance with the protocol, ICH-GCP requirements, and standard operating procedures (SOPs) for...
Saudi FDA’s New Pricing Guidelines and Impact on the Region
In a highly evolving regional pricing environment, Saudi Arabia (KSA) is no exception. The Saudi Food and Drug Authority (SFDA) has been periodically reviewing its pricing mechanisms and criteria so that the country becomes a regional reference for the prices of pharmaceutical products. What followed is a change in the pricing strategy by SFDA and a shift from price takers to price makers.
Webinar: Regulatory Strategy in the EAEU and Rest of CIS Countries
Regulatory strategy in EAEU and CIS regions differ from other regions as market access to these countries can be a real challenge due to various local regulations. However, it is only a matter of experience and adequate know-how. This webinar focuses on choosing your...
CMC: Effective Writing Of IND And IMPD
This artical focuses on best practices in delivering an effective CMC writing strategy when writing an IND or IMPD.
